



**Human Vaccines & Immunotherapeutics** 

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/khvi20

# COVID-19 vaccine willingness prior to and during the COVID-19 vaccination rollout in Australia

Bing Wang, Rebecca Nolan, Benjamin Krumeich, Katina D'Onise & Helen Marshall

**To cite this article:** Bing Wang, Rebecca Nolan, Benjamin Krumeich, Katina D'Onise & Helen Marshall (2022) COVID-19 vaccine willingness prior to and during the COVID-19 vaccination rollout in Australia, Human Vaccines & Immunotherapeutics, 18:5, 2079345, DOI: <u>10.1080/21645515.2022.2079345</u>

To link to this article: <u>https://doi.org/10.1080/21645515.2022.2079345</u>

<b>8</b> © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.	+ View supplementary material 🖸
Published online: 08 Jun 2022.	$\fbox$ Submit your article to this journal $\boxdot$
Article views: 1287	View related articles 🗹
Uiew Crossmark data 🗹	Citing articles: 1 View citing articles 🗹

#### **RESEARCH PAPER**

OPEN ACCESS Check for updates

Taylor & Francis

Taylor & Francis Group

# COVID-19 vaccine willingness prior to and during the COVID-19 vaccination rollout in Australia

Bing Wang<sup>a,b</sup>, Rebecca Nolan<sup>c</sup>, Benjamin Krumeich<sup>c</sup>, Katina D'Onise<sup>d,e</sup>, and Helen Marshall (D<sup>a,b</sup>

<sup>a</sup>Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, Australia; <sup>b</sup>Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, Australia; <sup>c</sup>Epidemiology Branch, Prevention and Population Health Directorate, Wellbeing SA, Adelaide, Australia; <sup>d</sup>Prevention and Population Health Directorate, Wellbeing SA, Adelaide, Australia; <sup>e</sup>School of Public Health, The University of Adelaide, Adelaide, Australia

#### ABSTRACT

This study aimed to assess vaccine willingness, and the reasons why respondents were not likely to receive COVID-19 vaccine prior to and during the COVID-19 vaccine rollout. This cross-sectional survey (n = 5,130) was conducted between January and April 2021 in South Australia, Australia. Weighted multiple logistic regression was performed to assess the association between sociodemographic/health factors and outcome measures. The percentage of respondents who stated they were very likely to get vaccinated fluctuated between 50% and 78% during the survey period. The willingness of receiving COVID-19 vaccination was significantly lower among women than men (aOR: 0.70) and higher among adults ≥50 years (aOR: 1.82 for 50–69 years and aOR: 3.01 for  $\geq$ 70 years vs 16–29-year olds). Other factors significantly associated with higher willingness were ≥Year 12 education (aOR: 2.50 for Year 12/TAFE/certificate/ diploma vs <Year 12 education; aOR: 1.44 for bachelor's degree or higher vs <Year 12 education), highest socioeconomic level vs lowest socioeconomic level (aOR: 1.75), and unpaid work/retirement/other vs unemployment (aOR: 1.77). Other factors such as being Aboriginal, not being married, not having chronic illness, and/or culturally and linguistically diverse backgrounds were identified to be significantly related to low confidence in vaccine safety, perceived low risk of disease and/or perceived lack of information. Parents or caregivers were significantly less willing for their child to be vaccinated compared to people in general (OR: 0.62). Targeted campaigns to improve uptake need to include appropriate messaging about vaccine safety and disease burden in addition to strategies to improve access to less willing groups.

# Introduction

At the end of 2019, a novel coronavirus (SARS-CoV-2) was first identified during an outbreak that emerged in Wuhan, the capital city of the Hubei Province, China. It has rapidly spread, resulting in a global pandemic.<sup>1</sup> The COVID-19 pandemic has had a severe impact on public health, daily life, and economies around the world. The pandemic has led to a significant loss of human life around the world and key challenges have been the emergence of new variants of the virus, and how quickly vaccines could be rolled out to the community.<sup>2</sup> The economic and social disruption caused by the pandemic is overwhelming: tens of millions of people are at risk of falling into extreme povertyliving on less than \$2 a day, while the number of undernourished people, estimated at nearly 690 million in 2020.<sup>3</sup> In Australia, it was reported that there were almost four times as many deaths caused by COVID-19 in the lowest socioeconomic group compared with the highest socioeconomic group, and agestandardized mortality rates were 2.6 times as high.<sup>2</sup> Massive vaccination against SARS-CoV-2 infection is considered the most promising approach for ending the pandemic.<sup>4</sup> The development and high uptake of vaccines is essential to combat the pandemic.<sup>5</sup> Case numbers of COVID-19 due to the Omicron

**ARTICLE HISTORY** 

Received 20 March 2022 Revised 2 May 2022 Accepted 14 May 2022

**KEYWORDS** COVID-19 vaccines; vaccine willingness

variant are rapidly increasing around the world. Among the 257,337 sequences uploaded to GISAID, a global genomic data sharing platform, with specimens collected from 23 March to 21 April 2022, 256,684 (99.7%) were Omicron.<sup>6</sup> WHO has warned that the Omicron variant should not be perceived as mild and still presents a serious risk to the health systems, although disease severity seems to be less than with the Delta variant. COVID-19 vaccines not only protect people from the variants currently in circulation including Omicron but are also likely to offer protection against severe disease including hospitalizations and ICU admissions and deaths due to future mutations of circulating variants.<sup>7</sup> South Australia has its highest daily number of COVID-19 cases on record in April 2022.8 It was initially expected that 85% of the eligible Australian population including 5-16 year-olds would need to be fully vaccinated with two doses of COVID-19 vaccines to achieve herd immunity.9 Although the second-dose vaccine coverage has reached >95% in people over the age of 16 in Australia,<sup>10</sup> strong evidence has indicated that booster doses of COVID-19 vaccines are required to increase protection against infection with the Omicron variant.<sup>11</sup> It is now recommended to receive COVID-19 booster

CONTACT Helen Marshall Alen.marshall@adelaide.edu.au 🗈 Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, North Adelaide, South Australia 5006, Australia

 $\ensuremath{\textcircled{\sc 0}}$  2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

Bupplemental data for this article can be accessed on the publisher's website at https://doi.org/10.1080/21645515.2022.2079345

vaccination for anyone aged 16 and older who has completed their two-dose COVID-19 vaccination in Australia.<sup>11</sup> However, only 52.4% of eligible population received the booster vaccinations.<sup>10</sup> The COVID-19 vaccines play a critical role in preventing deaths, Intensive Care Unit admissions, and hospitalization caused by COVID-19 infections. The success of vaccine rollout depends on very high vaccine acceptance and uptake to fight further waves of COVID-19 infections. There has been an urgent need to understand the attitudinal and behavioral drivers in order to inform community-led communication strategies to build trust and optimize COVID-19 vaccine uptake.

In surveys conducted during the initial wave of the pandemic, more than 80% of participants indicated that they would receive the COVID-19 vaccine.<sup>12,13</sup> In a survey study, willingness to vaccinate was higher among Australians in April 2020. However, the survey was repeated in July-August and December 2020 showing willingness to vaccinate against COVID-19 decreased over time.<sup>14</sup> In a longitudinal survey, after a large decline in vaccine willingness was observed between August 2020 and January 2021,<sup>15</sup> the survey data were collected again in April and August 2021 showing that although vaccine willingness did not decrease further there were still several sub-populations that remained hesitant about COVID-19 vaccination.<sup>16,17</sup> It is likely that population attitudes toward COVID-19 vaccine will fluctuate with the waves of the pandemic, necessitating regular tracking of vaccine confidence among different population groups to ensure public health campaigns remain responsive to community vaccine sentiments. In parent surveys conducted before and after the vaccine rollout, higher vaccine hesitancy or refusal was demonstrated among parents.<sup>17-20</sup>

Using survey data collected from a representative sample with a large sample size, including parents and caregivers, to accurately identify the key factors associated with COVID-19 vaccine willingness and concerns, is essential to inform public health messaging and communication strategies for effectively promoting the COVID-19 vaccine in targeted groups.

Our study aimed to assess vaccine willingness and determine sociodemographic and health factors influencing public attitudes toward COVID-19 vaccine prior to and during the COVID-19 vaccine rollout.

#### Methods

#### Study design and data sources

This study used a cross-sectional survey design. The South Australian Population Health Survey (SAPHS) is an ongoing state-wide population-level survey used to implement this study in Australia. The SAPHS is managed by Wellbeing SA —a state government agency within the Health Portfolio. Wellbeing SA has been collecting population-level data on the health and wellbeing of South Australians since 2002. Data are collected every month on overall health status, health service utilization, chronic conditions, cancer prevention, disability and carers, risk factors (biomedical, protective, and behavioral), food security, mental health, wellbeing, and disadvantage and inequity. Survey questions are developed in consultation with a broad range of stakeholders, to ensure the questions asked in the SAPHS are most appropriate to measure and monitor current disease trends, health service use, and health and lifestyle behavior. All questions are pilot tested when they are inserted into the survey. Some questions are from validated tools, while others are derived from national datasets. In preparation for the COVID-19 vaccine rollout, questions were included in the SAPHS to monitor the vaccine acceptance and confidence in vaccine safety in the South Australian population. The vaccination questions were derived from questions being asked by the Commonwealth Department of Health. The only data regarding COVID-19 vaccine attitudes were presented in the manuscript.

A probability-based, dual-frame sample of South Australian residents was selected using random digit dialing. Standard deduplication and weighting procedures for the dual overlapping frames were administered. As the SAPHS is a population-level survey, the only inclusion criteria were that respondents be residents of South Australia with access to a telephone. The data collector was able to conduct interviews in selected languages other than English (e.g. Greek, Arabic, and Vietnamese). For selected persons aged 15 years or younger, a parent/guardian proxy completed the interview on their behalf.

Informed verbal consent was obtained prior to the survey commencing. Once a person has consented to participate, the survey took approximately 20 min to complete. The participant might choose to be contacted at an alternative time or day that was most suitable for them. Participants could choose to skip questions during the interview and could withdraw their consent to participate in the survey at any time.

The only condition of the survey respondents was to be residents of South Australia. Potential respondents were contacted in the first instance to assess eligibility and then invited to participate in the survey. Participants were asked if they reside in South Australia and for their postcode.

#### Data collection

Data were collected using computer assisted telephone interviewing. To maximize participation, respondents were also offered the option of completing the survey on-line by receiving a unique hyperlink. The data presented in this paper were collected from 4 January to 30 April 2021 in South Australia, Australia. The cooperation rate<sup>21</sup>during this time frame was 64.2%.

Respondents were asked about their willingness to get vaccinated against COVID-19. If respondents did not state that they were very likely to get vaccinated, they were asked what would prevent them from considering being vaccinated against COVID-19. Reasons were grouped by themes in the analyses: 1) vaccine safety concerns; 2) a low perceived risk of infection; 3) vaccine effectiveness concerns; 4) perceived lack of information; and 5) general vaccine refusal. Respondents were also asked if they thought the vaccines were safe (Table S1).

# Statistical analysis

Data were presented by various population subgroups of sociodemographic and health characteristics. Socio-Economic Index For Areas (SEIFA) quintiles were presented according to the definition from the Australian Bureau of Statistics<sup>22</sup> using the respondent's postcode and suburb. As a proxy for respondents who are culturally and linguistically diverse, the respondent's country of birth (COB) was divided into two broad categories: English-speaking countries and non-English-speaking countries. Respondents who were born in Australia, the United Kingdom, Ireland, the United States of America, New Zealand, Canada, and South Africa are included in the Englishspeaking background category. All other respondents were included in the non-English speaking background category.<sup>23</sup> Health outcomes presented in the analyses were self-reported based on whether the respondent had even been told by a doctor or nurse they had a chronic condition. Aboriginal was used in this document respectfully as an all-encompassing term for Aboriginal and Torres Strait Islander people, health, and culture.

The predictor variables comprised of age, gender, Aboriginal identification, SEIFA, marital status, educational attainment, employment status, COB, area of residence, presence of chronic conditions, and presence of a mental health condition. In addition, a binary variable was created to indicate whether respondents had completed the survey before or after the implementation of the COVID-19 vaccination program. In Australia, the COVID-19 vaccine rollout commenced on 22 February 2021. Household income was not included as 25% of respondents answered "don't know" or preferred not to say.

Since ordinal logistic regression models did not demonstrate adequate fit, logistic regression models were used, defining the outcome as 1 if a respondent answered "very likely/confident" and 0 for any other responses. Answers 1– 7 and 9–12 to the question regarding the reasons why they were not very likely to receive the COVID-19 vaccine were grouped by themes. Logistic regression was performed for each theme to investigate factors associated with the reasons for vaccine hesitancy or refusal. The outcome was defined as 1 if a respondent selected any response relevant to the group theme. If a respondent who answered "very likely" to the vaccine willingness question or did not select any response relevant to the group theme, the outcome was "0".

Univariate and multiple logistic regression analyses were performed to test association between predictor variables and outcome measures. All the above-mentioned covariates with a *p*-value  $\leq 0.20$  on a univariate analysis of association with an outcome measure were included in a multivariate logistic model. All results presented in the descriptive tables and regression analyses were weighted. Raking was used to weight respondents incorporating various population characteristics (sex, age, area of residence, country of birth, dwelling status, marital status, education level, employment status, household size) to more closely reflect the South Australian population using benchmarks derived from the June 2016 ABS Census data. The weighting process ensured our findings were representative of the South Australian population. Adjustment to the demographic composition of the sample may cause variability in numbers for the unweighted and weighted populations.

### Results

# Study population

This survey was conducted in 5,130 South Australians between 4 January and 30 April 2021 including 4,484 respondents aged  $\geq$ 16 years and 646 parents or caregivers answering questions on behalf of their child aged less than 16 years.

The response option "I have already been vaccinated" to the question of COVID-19 vaccine willingness was introduced on 7 April 2021 due to the expansion of the rollout to Phase 1b on 23 March 2021. These respondents (n = 85) who were vaccinated were excluded from the sample, as our analyses were based on respondents who had not yet been vaccinated and assessed their intention to vaccinate against COVID-19. Table 1 shows the weighted and unweighted sociodemographic and health characteristics of both respondents aged  $\geq 16$  years and parents/caregivers. Finally, 4,400 (weighted n = 4,067) respondents aged  $\geq 16$  years were included in the weighted and adjusted regression analyses.

# Vaccine willingness

Of respondents aged  $\geq$ 16 years, 60.1% indicated they were very likely to be vaccinated with COVID-19 vaccine (Table S2). Parent/guardian respondents were less likely to agree with their child receiving the vaccine compared to those  $\geq$ 16 years (48.2% vs 60.1% very likely to get vaccinated; OR: 0.62 [95% CI, 0.50–0.76]). The likelihood of vaccination against COVID-19 was highest (weighted percentage: 77.9%) in early March following the first COVID-19 vaccinations being given (Figure 1). This was followed by a second peak in late April.

In the weighted and adjusted logistic model, age, gender, socioeconomic status, educational attainment, and COVID-19 vaccine rollout were associated with the intention to receive the COVID-19 vaccine (Table 2). The willingness to receive COVID-19 vaccination was lower among women, and higher among adults aged  $\geq$ 50 years, people with the highest SEIFA quantile, those completing high-school education or higher, and those with unpaid work/ retirement/other prior to the vaccine rollout.

# Confidence in vaccine safety

Eighty percent of people  $\geq 16$  years were either very confident (35.1%) or somewhat confident (46.1%) about vaccine safety (Table S3). In the weighted and adjusted logistic model, confidence in vaccine safety was lower among women, Aboriginal people, the unemployed, respondents with a non-English-speaking COB, and increased with years of age, education llevel, and socioeconomic advantage (Table S4). Confidence in vaccine safety reported by parents/caregivers on behalf of their child was lower than those respondents aged  $\geq 16$  years (27.2% vs 35.1% very confident).

	Medfined (n = 4,00)         Unweighted (n = 4,00)         Weighted (n = 1001)         Unweighted (n = 4,00)         Nomeline           w (95% (1)         n         % (1) <th>n (5D)) 1,900 2,166 2,166 1,900 1,900 1,90</th> <th>Neighted (n</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	n (5D)) 1,900 2,166 2,166 1,900 1,900 1,90	Neighted (n							
n $q_{0}$ (6%) (7)         n $q_{0}$ (6%) (7)         n $q_{0}$ (6%) (7)         n $q_{0}$ (6%) (7)         n           m (SD) $20$ (4%) (4%) (4%) (4%) (4%) (4%) (4%) (4%)	% (95% Cl)       n         50.5 (45.7–55.2)       335         9.5 (44.8–54.3)       336         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         4.7 (2.9–7.4)       26         17.8 (14.4–21.9)       117         192 (15.8–23.2)       127         192 (16.4–23.6)       117         192 (16.4–23.6)       117         192 (14.4–21.0)       118         17.3 (14.2–21.0)       118         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       149         25.8 (21.8–30.4)       123         399 (35.4–44.6)       267         21.7 (18.1–25.8)       147         18.2 (14.7–22.3)       108         95.6 (92.9–97.3)       24         75.7 (71.7–79.3)       193	ın (SD)) al and/or Torres Strait Islander Status	4		unweig		Weigł		Unwe	ighted (n = 645)
Interpretation         190 $67(44, 490)$ 188 $22(66, 491)$ 591         955 (45, 755)         335         336         335         336         335         336         335         336         335         336         335         336         335         336         335         336         335         336         335         336         336         335         336         336         335         336 <th>50.5 (45.7-55.2)       33.5         9.5 (44.8-54.3)       308         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.3 (92.6-97.1)       618         4.7 (2.9-7.4)       26         17.8 (14.4-21.9)       117         19.2 (15.8-32.2)       127         19.2 (16.4-23.6)       134         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       123         39.9 (35.4-44.6)       126         25.8 (21.8-30.4)       147         18.2 (14.7-2.23)       123         39.9 (35.4-44.6)       261         18.2 (14.7-2.23)       123         95.6 (92.9-97.3)       621         44.4 (2.6-7.1)       24         75.7 (77.7-28.3)       193         83.3 (79.3-86.6)</th> <th>ın (SD)) al and/or Torres Strait Islander Status</th> <th>4</th> <th>% (95% CI)</th> <th>u</th> <th>% (95% CI)</th> <th>ч</th> <th>% (95% CI)</th> <th>ц</th> <th>% (95% CI)</th>	50.5 (45.7-55.2)       33.5         9.5 (44.8-54.3)       308         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.3 (92.6-97.1)       618         4.7 (2.9-7.4)       26         17.8 (14.4-21.9)       117         19.2 (15.8-32.2)       127         19.2 (16.4-23.6)       134         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       123         39.9 (35.4-44.6)       126         25.8 (21.8-30.4)       147         18.2 (14.7-2.23)       123         39.9 (35.4-44.6)       261         18.2 (14.7-2.23)       123         95.6 (92.9-97.3)       621         44.4 (2.6-7.1)       24         75.7 (77.7-28.3)       193         83.3 (79.3-86.6)	ın (SD)) al and/or Torres Strait Islander Status	4	% (95% CI)	u	% (95% CI)	ч	% (95% CI)	ц	% (95% CI)
(b) $\frac{1}{200}$ $\frac{5}{201}$	20.2 (42, S-24.3)       535         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       645         9.1 (4.9)       618         4.7 (2.9-7.4)       26         19.2 (15, 8-23.2)       127         19.7 (16, 4-23.6)       127         19.7 (16, 4-23.6)       127         17.3 (14, 2-21.0)       118         17.3 (14, 2-21.0)       118         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       149         25.8 (21, 8-30.4)       123         39.9 (35, 4-44.6)       267         21.7 (18, 1-25.8)       147         18.2 (14, 7-22.3)       108         95.6 (92, 9-97.3)       24         75.7 (71, 7-79.3)       452         24.3 (20, 7-28.3)       193         83.3 (79.3-86.6)       541         16.7 (13, 4-20.7) </td <td>ın (SD)) al and/or Torres Strait Islander Status</td> <td>14</td> <td></td> <td>0 1 1</td> <td></td> <td>Č</td> <td></td> <td>L L</td> <td></td>	ın (SD)) al and/or Torres Strait Islander Status	14		0 1 1		Č		L L	
(a)         (b)         (c)         (c) <td>95.3 (92.6-97.1)       618         <math>4.7</math> (2.9-7.4)       618         <math>4.7</math> (2.9-7.4)       26         17.8 (14.4-21.9)       117         192 (15.8-23.2)       127         192 (15.8-23.2)       127         192 (15.8-23.2)       127         192 (16.4-23.6)       114         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       128         39.9 (35.4-44.6)       126         21.7 (18.1-55.8)       147         18.2 (14.7-22.3)       108         95.6 (92.9-97.3)       621         44. (2.6-7.1)       24         75.7 (71.7-79.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       561         16.7 (13.4-20.7)       561</td> <td>ın (SD)) al and/or Torres Strait Islander Status intile</td> <td>ſ</td> <td>+6./ (44.5–49.0) 3 3 (51 0–55 5)</td> <td>1,858 2 540</td> <td>42.2 (40.8–43./) 57 8 (56 3–59 2)</td> <td>504 495</td> <td>0.5 (45./-25.2) 2.02 49 5 (44 8–54 3)</td> <td>335 308</td> <td>22.1 (48.2–56.0) 47 9 (44 0–51 8</td>	95.3 (92.6-97.1)       618 $4.7$ (2.9-7.4)       618 $4.7$ (2.9-7.4)       26         17.8 (14.4-21.9)       117         192 (15.8-23.2)       127         192 (15.8-23.2)       127         192 (15.8-23.2)       127         192 (16.4-23.6)       114         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       128         39.9 (35.4-44.6)       126         21.7 (18.1-55.8)       147         18.2 (14.7-22.3)       108         95.6 (92.9-97.3)       621         44. (2.6-7.1)       24         75.7 (71.7-79.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       561         16.7 (13.4-20.7)       561	ın (SD)) al and/or Torres Strait Islander Status intile	ſ	+6./ (44.5–49.0) 3 3 (51 0–55 5)	1,858 2 540	42.2 (40.8–43./) 57 8 (56 3–59 2)	504 495	0.5 (45./-25.2) 2.02 49 5 (44 8–54 3)	335 308	22.1 (48.2–56.0) 47 9 (44 0–51 8
The interaction         735         713 (13, -10, 0)         233         56 (1-6, 1)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         73         73 (15, -16, 0)         74         73 (15, -12, 0)         74         73 (15, -12, 0)         17         74         73 (15, -12, 0)         17         74         73 (15, -12, 0)         17         76         71         73 (15, -12, 0)         75         74         73 (15, -12, 0)         17         74         73 (16, -12, 0)         76         73 (16, -12, 0)         76         73 (16, -12, 0)         76         73 (16, -12, 0)         76         73 (16, -12, 0)         76         73 (16, -12, 0)         76         73 (16, -12, 0)         176         74         <	95.3 (92.6–97.1) 618 4.7 (2.9–7.4) 26 17.8 (14.4–21.9) 117 192 (15.8–23.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 25.8 (21.8–30.4) 149 177 182 (14.7–22.3) 123 399 (35.4–44.6) 267 147 182 (14.7–22.3) 193 83.3 (79.3–86.6) 521 44. (2.6–7.1) 24 75.7 (71.7–79.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 561 14.1 (11.0–17.9) 84	al and/or Torres Strait Islander Status Intile	50.1 (1	8.4)		59.4 (15.6)	1,001	9.1 (4.9)	645	9.0 (4.6)
1208         237(27-540)         731         135(77-540)         731         135(77-540)         731         136(6-16)           1 and/or Torres Strat Islander Status         300         200(73-96)         1287         233(65-616)         73         353(77-910)         106           1 and/or Torres Strat Islander Status         390         200(73-96)         1287         233(75-910)         73         533(72-910)         76           1 and/or Torres Strat Islander Status         390         200(73-92)         610         136(47-16.0)         73         472(29-74)         01           1 and the         770         201(73-20)         640         158(47-16.0)         173         472(29-74)         173           1 and         771         177(104-010)         78         233(77-40.0)         174         173         174-210         114           1 and         721         177(104-210)         78         233(77-40.0)         174         173         174-210         114           1 and         233(77-90)         78         233(77-90)         174         173         174-210         114           1 and         233(77-90)         78         233(77-90)         174         173         174         174	95.3 (92.6–97.1) 618 4.7 (2.9–7.4) 26 17.8 (14.4–21.9) 117 19.2 (15.8–23.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 25.8 (21.8–30.4) 149 173 14.7 (11.–25.8) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84	al and/or Torres Strait Islander Status Intile	-	7.3 (15.2–19.6)		5.8 (5.1–6.5)				
1401         344 (32,5-56)         2.073         4.73 (68,5-48.3) $2.73$ 6.13 (1.1-1.8) $4.7$ $4.7$ (2.5-7.4) $5.6$ 1 and/or Torres Stratt binduct Status         370         98.0 (1.2-1.5) $4.3$ $5.3$ (32,5-3.0) $5.6$ 1 mile         370         98.0 (1.2-1.5) $6.1$ $1.4(1.1-1.8)$ $4.7$ $4.7$ (2.5-7.4) $5.6$ 1 mile         21 $1.32$ (10,2-1.6) $5.8$ $1.35$ (10,2-1.6) $1.7$ $6.10$ $4.7$ $4.7$ (2.5-7.4) $5.6$ 1 mile         21 $1.32$ (10,2-1.6) $5.8$ $1.35$ (10,2-1.6) $1.9$ $1.75$ (10,2-1.6) $1.76$ 1 mile         21 $1.32$ (10,5-1.6) $2.8$ $2.32$ (11-2.30) $1.96$ $1.36$ $1.36$ (16,6-1.6) $1.96$ 1 mile         21 $1.32$ (10,5-1.6) $2.8$ $2.32$ (11-3.93) $2.9$ $2.36$ (15,6-3.6) $1.96$ 1 mile         2.32 (1.5-1.6) $1.36$ $2.32$ (11-2.93) $1.96$ $2.32$ (11-2.93) $1.96$ 1 mile         2.32 (1.2-5.23) $2.32$ (2.13-2.23)	95.3 (92.6–97.1) 618 4.7 (2.9–7.4) 26 17.8 (14.4–21.9) 117 19.2 (15.8–23.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 25.8 (21.8–30.4) 149 118 25.8 (21.8–30.4) 149 182 (14.7–22.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 182 (14.7–22.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 84 14.1 (11.0–17.9) 84	al and/or Torres Strait Islander Status intile	2	9.7 (27.5–32.0)	781	17.8 (16.6–18.9)				
Inductor         73         165 (72-199)         128         233 (279-306) $\cdot \cdot \cdot \cdot$ Inductor         390         960 (97-92)         431         966 (92-369)         953         953 (25-97)         610           Inductor         390         960 (71-92)         61         14(11-18)         77         613 (27-193)         61           Inductor         390         960 (71-92)         61         14(11-18)         77         613 (27-294)         78           Inductor         311         217 (12-120)         64         154 (11-18)         77         613 (27-294)         171           Inductor         311         217 (12-130)         98         323 (21-294)         171           Inductor         311         177 (12-130)         98         233 (21-240)         171           Inductor         311         312 (21-240)         313 (21-240)         171         171           Inductor         311 (21-213)         313         323 (21-243)         323 (21-243)         171           Inductor         311 (21-213)         313         323 (21-243)         323 (21-243)         171           Inductor         311 (21-213)         313         323 (21-423)         323 (21-423) <t< td=""><td>95.3 (92.6–97.1) 618 4.7 (2.9–7,4) 26 17.8 (14.4–21.9) 117 19.2 (15.8–33.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 25.8 (21.8–30.4) 149 118 25.8 (21.8–30.4) 149 18.2 (14.7–22.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84</td><td>nal and/or Torres Strait Islander Status <sup>unintile</sup></td><td>'n</td><td>4.4 (32.6–36.4)</td><td>2,079</td><td>47.3 (45.8–48.7)</td><td></td><td></td><td></td><td></td></t<>	95.3 (92.6–97.1) 618 4.7 (2.9–7,4) 26 17.8 (14.4–21.9) 117 19.2 (15.8–33.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 25.8 (21.8–30.4) 149 118 25.8 (21.8–30.4) 149 18.2 (14.7–22.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84	nal and/or Torres Strait Islander Status <sup>unintile</sup>	'n	4.4 (32.6–36.4)	2,079	47.3 (45.8–48.7)				
In and/or Torkes Start Islander Status $300$ $60071-98.7$ $411$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $61$ $141(1-1.6)$ $26$ $121(10-2-7.4)$ $26$ unitie $211$ $220(12-2.4)$ $961$ $211(10-2.2)$ $931(16-2.2)$ $121(16-2.2)$ </td <td>95.3 (92.6–97.1) 618 4.7 (2.9–7.4) 26 17.8 (14.4–21.9) 117 19.2 (15.8–23.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 118 25.8 (21.8–30.4) 149 182 14.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (18.1–25.8) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 661 14.1 (11.0–17.9) 84</td> <td>nal and/or Torres Strait Islander Status unintile</td> <td>-</td> <td>8.5 (17.2–19.9)</td> <td>1,287</td> <td>29.3 (27.9–30.6)</td> <td></td> <td></td> <td></td> <td></td>	95.3 (92.6–97.1) 618 4.7 (2.9–7.4) 26 17.8 (14.4–21.9) 117 19.2 (15.8–23.2) 127 19.7 (16.4–23.6) 134 17.3 (14.2–21.0) 118 25.8 (21.8–30.4) 149 118 25.8 (21.8–30.4) 149 182 14.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (18.1–25.8) 123 39.9 (35.4–44.6) 267 14.7 (18.1–25.8) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 661 14.1 (11.0–17.9) 84	nal and/or Torres Strait Islander Status unintile	-	8.5 (17.2–19.9)	1,287	29.3 (27.9–30.6)				
$ \begin{array}{l lllllllllllllllllllllllllllllllllll$	95.3 (92.6-9.7.1)       618         4.7 (2.9-7.4)       26         17.8 (14.4-21.9)       117         19.2 (15.8-23.2)       127         19.7 (16.4-23.6)       134         17.3 (14.2-21.0)       118         17.3 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         17.1 (14.1-25.8)       147         18.2 (14.7-22.3)       108         95.6 (92.9-97.3)       621         4.4 (2.6-7.1)       24         75.7 (71.7-79.3)       452         24.3 (20.7-28.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       107         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84	iintiie Airtiintii								
India $221(2)-244(1)$ $01$ $10(1,1-10)$ $10$ $10(1,1-10)$	4.7       (2.5-7.4)       20         17.8       (14.4-21.0)       117         19.2       (15.8-23.2)       127         19.7       (16.4-23.6)       134         17.3       (14.2-21.0)       118         17.3       (14.2-21.0)       118         25.8       (21.8-30.4)       149         25.8       (21.8-30.4)       149         25.8       (21.8-30.4)       149         25.8       (21.8-30.4)       149         25.8       (21.8-30.4)       149         29.9       (35.4-44.6)       267         21.7       (18.1-25.8)       147         18.2       (14.7-22.3)       108         95.6       (92.9-97.3)       267         4.4       (2.6-7.1)       24         75.7       (71.7-79.3)       452         24.3       (20.7-28.3)       193         83.3       (79.3-86.6)       538         16.7       (13.4-20.7)       107         85.9       (82.1-89.0)       561         14.1       (11.0-17.9)       84	unintile		(//1–98./) (9/.1–98./) مرح د ۱٬ مرح	4,318 61	98.6 (98.2–98.9)	953 47	95.3 (92.6–97.1) 17 0 0 7 1	618 26	96.0 (94.1–97.2 107.0 5 07
	17.8 (14.4-21.9)       117         19.2 (15.8-23.2)       127         19.7 (16.4-23.6)       134         19.7 (16.4-23.6)       134         17.3 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       123         399 (35.4-44.6)       267         21.7 (18.1-25.8)       147         182 (14.7-22.3)       108         95.6 (92.9-97.3)       621         4.4 (2.6-7.1)       24         75.7 (71.7-79.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       107         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84	uintile		(6.7-C.1) N.7	10	(0.1 – 1.1) +.1	t t	4.7 (2.3-1.4)	70	(6.0-0.7) 0.4
	19.2 (15.8-23.2)       127         19.7 (16.4-23.6)       134         17.3 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       123         39.9 (35.4-44.6)       267         21.7 (18.1-25.8)       147         18.2 (14.7-22.3)       108         95.6 (92.9-97.3)       621         4.4 (2.6-7.1)       24         75.7 (71.7-79.3)       452         24.3 (20.7-28.3)       193         833 (79.3-86.6)       538         16.7 (13.4-20.7)       107         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84		÷	0 1 (17 3–21 0)	694	15.8 (14.7–16.9)	179	178 (144–219)	117	18 1 (15 3–21 3
	19.7 (16.4-23.6)       134         17.3 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         17.3 (14.2-21.0)       118         20.2 (16.6-24.3)       123         39.9 (35.4-44.6)       267         21.7 (18.1-25.8)       147         18.2 (14.7-22.3)       108         95.6 (92.9-97.3)       621         4.4 (2.6-7.1)       24         75.7 (71.7-79.3)       452         24.3 (20.7-28.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       107         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84		- ~	1.7 (19.9–23.5)	958	21.8 (20.6–23.0)	192	19.2 (15.8–23.2)	177	19.7 (16.8–22
	173 (14.2-21.0)       118         25.8 (21.8-30.4)       149         25.8 (21.8-30.4)       149         30.9 (35.4-44.6)       267         31.7 (18.1-25.8)       147         39.9 (35.4-44.6)       267         21.7 (18.1-25.8)       147         18.2 (14.7-22.3)       108         95.6 (92.9-97.3)       621         4.4 (2.6-7.1)       24         75.7 (71.7-93.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       193         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84		2.7	2.5 (20.7–24.4)	981	22.3 (21.1–23.6)	198	19.7 (16.4–23.6)	134	20.8 (17.8–24.7
t quintle         776         191 (17+209)         988         225 (213-327)         258 (218-304)         149           Latus         1         1         2 <th2< th="">         2         2</th2<>	25.8 (21.8–30.4) 149 25.8 (21.8–30.4) 149 20.2 (16.6–24.3) 20.2 (16.6–24.3) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 108 95.6 (92.9–97.3) 6.21 4.4 (2.6–7.1) 2.4 75.7 (71.7–9.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84		-	7.7 (16.0–19.6)	778	17.7 (16.6–18.8)	174	17.3 (14.2–21.0)	118	18.3 (15.5–21.5)
Latus         Latus         Latus         Latus           1, tatus $184$ $458$ $173$ - $481$ $1708$ $392$ $377$ - $406$ $206$ lose $1213$ $196-735$ $2039$ $603$ $932$ $77-406$ $206$ lose $213$ $196-732$ $233$ $202-144$ $78$	202 (16.6–24.3) 39.9 (35.4–44.6) 21.7 (18.1–25.8) 18.2 (14.7–22.3) 95.6 (92.9–97.3) 4.4 (2.6–7.1) 4.4 (2.6–7.1) 2.4 75.7 (71.7–79.3) 452 243 (20.7–28.3) 193 83.3 (79.3–86.6) 107 85.9 (82.1–89.0) 84 14.1 (11.0–17.9) 84		-	9.1 (17.4–20.9)	988	22.5 (21.3–23.7)	259	25.8 (21.8–30.4)	149	23.1 (20.0–26.5)
Mathematical conditions $1847$ $458$ $452$ $17.96$ $542$ $17.953$ $608$ $534.623$ $608$ $534.623$ $608$ $534.623$ $608$ $534.623$ $608$ $534.623$ $608$ $542$ $(19.5-232)$ $833$ $201$ $(19.0-21.4)$ $747$ 7277 $727$ 7277<	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–93.3) 193 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84	l status								
ied/de $2,16$ $5,12$ $5,12$ $6,03$ $603(534-62.3)$ $603(534-62.3)$ arthan Yar 12 education $861$ $2,13$ $19,6-232$ $883$ $202(19,0-214)$ $2.775$ $77,17$ $158-186$ $1463$ $332(21,-343)$ $900$ $900$ $113$ $19,6-232$ $883$ $202(19,0-214)$ $900$ $861$ $2,13$ $19,6-232$ $883$ $202(19,0-214)$ $900$ $861$ $2,13$ $19,6-232$ $883$ $202(19,0-214)$ $900$ $1232$ $453(4,5-56)$ $152$ $352(3,5-46)$ $152$ $9000$ $1222$ $453(4,5-56)$ $2173$ $49,4(7,9-50)$ $9000$ $1230$ $2222$ $423(25-56)$ $2173$ $49,4(7,9-50)$ $9000$ $1230$ $2222$ $323(3,5-56)$ $2173$ $49,4(7,9-50)$ $9000$ $1230$ $2232$ $323(3,5-56)$ $2173$ $49,4(7,9-50)$ $9000$ $1230$ $2232$ $323(3,5-56)$ $2173$ $202(66-34)$ $9000$ $1230$ $2232$ $202(62,3-29)$ $399(35,4-46)$ $202(66-34)$ $9000$ $1230$ $202(24,2-3)$ $202(66-34)$ $123$ $9000$ $1330$ $233(3,5-56)$ $1146$ $260(24,8-7)$ $217(18,1-2,3)$ $9000$ $1320$ $123(1-6,1-12)$ $49,4(7,2-7)$ $99,4(7,2-7)$ $212(4,7-2,3)$ $9000$ $1300$ $213(21-6,1)$ $123(26-6,10)$ $113(10,-12,2)$ $414(7,2-7,2)$ $212(4,7-2,2)$ $9000$ $11300$ $113(10,-12,2)$ $113(10$	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 24 75.7 (71.7–79.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			!5.8 (43.5–48.1)	1,708	39.2 (37.7–40.6)				
	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–29.3) 193 83.3 (79.3–86.6) 193 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			:4.2 (51.9–56.5)	2,653	60.8 (59.4–62.3)				
001 $2.13(192-3.2)$ $083$ $2.2(19J-0.1.4)$ $622$ $17.1(15.8-18.6)$ $1468$ $33.5(3.2.1-3.4)$ $33.5(3.2.1-3.4)$ $182$ $4.5(3.6-5.6)$ $172$ $3.5(3.0-4.0)$ $1.52$ $3.5(3.0-4.0)$ $1222$ $548(5.2.5-5.6)$ $172$ $3.5(3.0-4.0)$ $3.2(3.2.1-36.3)$ $122$ $1.58$ $408(38.6-42.9)$ $2.072$ $4.72(45.7-48.6)$ $123$ $1.716$ $300(27.8-32.1)$ $1278$ $3.59(4.47.9-50.9)$ $3.99$ $3.42(3.1-36.3)$ $123$ $1.216$ $300(27.8-32.1)$ $1.78$ $3.59(4.4.6)$ $2.67$ $1.74$ $1.216$ $300(27.8-32.1)$ $1.716$ $2.60(2.4.2-282)$ $1.146$ $2.60(2.4.8-27.4)$ $123$ $1.206$ $714(99.4-734)$ $3.820(24.4-26.9)$ $3.82(87.7-89.6)$ $9.97$ $9.92(9.2-97.3)$ $0.21$ $3332$ $82.0(11-99.9)$ $4.97$ $11.3(10.4-12.3)$ $4.4$ $4.4(2.6-7.1)$ $2.4$ $729$ $82.0(24.7-83.7)$ $182$ $12.2(77.7-27.3)$ $1$	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–55.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 24 75.7 (71.7–79.3) 193 83.3 (79.3–86.6) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84		Ċ		.00					
2220 $171$ $172$ $325$ $3277$ $3277$ $3277$	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–55.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 24 75.7 (71.7–79.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			1.3 (19.6–23.2) 1 6 (50 5–63 7)	883 2 020	20.2 (19.0-21.4)				
182 $45(3,6-56)$ 152 $35(3,0-40)$ 1658 $408(35,6-26)$ $152$ $35(3,0-40)$ 1568 $408(35,6-26)$ $2075$ $472(457,-486)$ 1568 $408(35,6-26)$ $2173$ $494(479-509)$ 1216 $300(278-32.1)$ $1216$ $359(35,4-346)$ $123$ 1389 $342(32,-123)$ $1778$ $359(64,-234)$ $123$ 338 $98(5-112)$ $460$ $105(96-114)$ $218$ $117/(14,-223)$ $106$ 332 $882(87,-896)$ $560(24,-244)$ $128$ $127/(12,-283)$ $107$ 332 $882(87,-896)$ $957$ $956(929-973)$ $108$ $729$ $180(16,-199)$ $497$ $113(10,-123)$ $44$ $44.(2,6-71)$ $24$ $729$ $180(16,-199)$ $387(87,-896)$ $573(71,-793)$ $108$ $1162$ $286(266-306)$ $1,400$ $318(30,-332)$ $243(20,-243)$ $123$ $2006$ $714(694-734)$ $3000$ $682(66,-695)$ $753(71,-793)$ $422$ $1,162$ $286(266-30,6)$ $1,400$ <td>20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–55.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–28.3) 193 83.3 (79.3–86.6) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84</td> <td></td> <td></td> <td>7 1 (15 8–18 6)</td> <td>1 468</td> <td>33.5 (32.1-34.9)</td> <td></td> <td></td> <td></td> <td></td>	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–55.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–28.3) 193 83.3 (79.3–86.6) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			7 1 (15 8–18 6)	1 468	33.5 (32.1-34.9)				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–55.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.3 (71.7–28.3) 193 83.3 (79.3–86.6) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84		-		202					
2.227 $548$ (52.5-56.9) $2.075$ $47.2$ (45.7-48.6) $1,658$ $40.8$ (38.6-42.9) $2.173$ $49.4$ (7.9-50.9) $1,589$ $34.2$ (32.1-36.3) $1.578$ $35.9$ (34.5-37.3) $202$ $202$ (16.6-24.3) $1216$ $300$ (27.8-32.1) $1.216$ $27.6$ (56.3-29.0) $399$ (35.4-44.6) $267$ $308$ $9.8$ (85-11.2) $460$ $10.5$ (9.6-11.4) $218$ $217$ (18.1-25.8) $147$ $1,064$ $26.2$ (24.2-28.2) $1,146$ $26.0$ (24.8-27.4) $182$ $182.$ (14.7-22.3) $108$ $3332$ $82.0$ (80.1-83.9) $3992$ $88.7$ (87.7-89.6) $957$ $95.6$ (92.9-97.3) $621$ $3332$ $82.0$ (80.1-83.9) $3992$ $88.7$ (87.7-89.6) $957$ $95.6$ (22.9-97.3) $24$ $2,906$ $714$ (69.4-73.4) $3,000$ $68.2$ (66.8-69.5) $757$ (71.7-79.3) $492$ $1,162$ $28.6$ (26.6-30.6) $1,400$ $31.8$ (30.5-33.2) $243$ $27.7$ (71.7-79.3) $452$ $1,162$ $28.6$ (26.6-30.6) $1,400$ $31.8$ (30.5-33.2) $243$ $23.7$ (37.7-28.3) $193$ $2,245$ $55.2$ (52.9-57.5) $2.845$ $64.7$ (63.2-66.1) $167$ (13.4-20.7) $107$ $2,232$ $72.1$ (69.9-74.1) $3.330$ $75.7$ (74.4-76.9) $860$ $85.9$ (82.1-99.0) $561$ $1,136$ $27.9$ (25.9-30.1) $1,070$ $24.3$ (23.1-25.6) $14.1$ (11.0-17.9) $961$	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–55.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 621 4.4 (2.6–7.1) 24 75.3 (71.7–79.3) 193 83.3 (79.3–86.6) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			4.5 (3.6–5.6)	152	3.5 (3.0–4.0)				
1,65840.8 (38.6-4.29)2,17349.4 (47.9-50.9) $1.578$ $3.59 (34.5-37.3)$ $2.02$ $2.02 (16.6-2.4.3)$ $1.23$ 1,216 $3.00 (27.8-32.1)$ $1.578$ $3.59 (34.5-37.3)$ $2.02$ $2.02 (16.6-2.4.3)$ $1.23$ $388$ $9.8 (8.5-11.2)$ $1.578$ $3.59 (34.5-37.2)$ $3.99$ $3.99 (35.4-44.6)$ $267$ $388$ $9.8 (8.5-11.2)$ $1.05 (9.6-11.4)$ $218$ $21.7 (18.1-25.8)$ $108$ $332$ $82.0 (801-83.9)$ $3.992$ $88.7 (877-89.6)$ $957$ $95.6 (92.9-97.3)$ $0.21$ $729$ $18.0 (16.1-19.9)$ $4.97$ $11.3 (10.4-12.3)$ $4.4$ $4.4 (2.6-7.1)$ $2.4$ $2.906$ $71.4 (69.4-73.4)$ $3.000$ $68.2 (668-69.5)$ $758$ $75.7 (71.7-79.3)$ $193$ $2.906$ $71.4 (69.4-73.4)$ $3.000$ $68.2 (668-69.5)$ $758$ $75.7 (71.7-79.3)$ $193$ $1,162$ $2.86 (266-30.6)$ $1,400$ $31.8 (30.5-33.2)$ $2.43$ $20.7-28.3$ $193$ $1,162$ $2.86 (266-30.6)$ $1,400$ $31.8 (30.5-33.2)$ $2.43$ $20.7-28.3$ $193$ $2,245$ $55.2 (52.9-57.5)$ $2,847 (63.2-66.1)$ $16.7 (13.4-20.7)$ $107$ $2,245$ $55.2 (95-747.1)$ $1,555$ $353 (33.9-36.8)$ $83.4$ $83.3 (79.3-86.6)$ $538$ $2,245$ $55.2 (95-75.5)$ $2,847 (63.2-66.1)$ $167 (13.2-66.1)$ $167 (13.4-20.7)$ $193$ $2,245$ $27.1 (69-7.41)$ $3.330$ $75.7 (74.4-76.9)$ $860$ $89.9 (82.1-89.0)$	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84		ιċ	4.8 (52.5–56.9)	2,075	47.2 (45.7–48.6)				
1,389 $34.2 (32.1-36.3)$ $1.578$ $359 (34.5-37.3)$ $202$ $202 (16.6-24.3)$ $123$ $1,216$ $300 (27.8-32.1)$ $1,216$ $27.6 (26.3-29.0)$ $399 (35.4-44.6)$ $267$ $398$ $9.8 (8.5-11.2)$ $460$ $10.5 (9.6-11.4)$ $218$ $21.7 (18.1-55.8)$ $147$ $398$ $9.8 (8.5-11.2)$ $460$ $10.5 (9.6-11.4)$ $218$ $21.7 (18.1-52.3)$ $108$ $3322$ $82.0 (801-83.9)$ $3892$ $88.7 (877-89.6)$ $957$ $95.6 (92.9-97.3)$ $621$ $729$ $18.0 (16.1-19.9)$ $497$ $11.3 (10.4-12.3)$ $44$ $4.4 (2.6-7.1)$ $24$ $2.906$ $71.4 (69.4-73.4)$ $3.000$ $682 (66.8-69.5)$ $758$ $75.7 (71.7-79.3)$ $452$ $1,162$ $28.6 (25.6-30.6)$ $1400$ $31.8 (30.5-33.2)$ $243$ $203.793.66.6$ $538$ $1,162$ $28.6 (25.6-30.6)$ $1,400$ $31.8 (30.5-33.2)$ $243$ $207.728.3$ $193$ $2,245$ $55.2 (52.9-57.5)$ $2,345$ $64.7 (63.2-66.1)$ $16.7 (13.4-20.7)$ $107$ $2,242$ $27.1 (699-74.1)$ $1.555$ $35.3 (33.9-36.8)$ $860$ $85.9 (82.1-89.0)$ $561$ $2,242$ $25.2 (52.9-57.5)$ $2,347$ $24.7 (53.2-66.1)$ $16.7 (13.4-20.7)$ $107$ $2,242$ $27.1 (699-74.1)$ $1,555$ $35.3 (33.9-56.8)$ $860$ $85.9 (82.1-89.0)$ $561$ $2,242$ $27.1 (57.9-30.1)$ $1,070$ $24.3 (23.1-25.6)$ $141$ $14.1 (11.0-17.9)$ $84$	20.2 (16.6–24.3)       123         39.9 (35.4–44.6)       267         21.7 (18.1–25.8)       147         18.1 (18.1–25.8)       147         18.2 (14.7–22.3)       108         95.6 (92.9–97.3)       621         4.4 (2.6–7.1)       24         75.7 (71.7–79.3)       452         24.3 (20.7–28.3)       193         83.3 (79.3–86.6)       538         16.7 (13.4–20.7)       107         85.9 (82.1–89.0)       561         14.1 (11.0–17.9)       84			0.8 (38.6–42.9)	2,173	49.4 (47.9–50.9)				
1,389 $3.42$ $3.2.1-36.3$ $1,578$ $35.9$ $34.5-37.3$ $202$ $202$ $16.624.3$ $123$ $1,216$ $3.00$ $27.8-32.1$ $1,216$ $27.6$ $(5.6.3-29.0)$ $399$ $39.9$ $(55.4-44.6)$ $267$ $388$ $9.8$ $(8.5-11.2)$ $1,146$ $26.0$ $24.8-27.4$ $182$ $118.2$ $(14.7-22.3)$ $108$ $1,064$ $26.2$ $24.2-28.2$ $1,146$ $26.0$ $24.8-27.4$ $182$ $112.2$ $108$ $3,332$ $82.0$ $(80.1-83.9)$ $3.892$ $88.7$ $(87.7-89.6)$ $957$ $95.6$ $92.9-97.3$ $621$ $3,332$ $82.0$ $(80.1-83.9)$ $3.892$ $88.7$ $(87.7-89.6)$ $957$ $95.6$ $92.9-97.3$ $621$ $729$ $18.0$ $(16.1-19.9)$ $497$ $11.3$ $(10.4-12.3)$ $44$ $4.4$ $(2.6-7.1)$ $24$ $2,906$ $71.4$ $(69.4-73.4)$ $3.000$ $68.2$ $(66.8-69.5)$ $758$ $75.7$ $(71.7-79.3)$ $193$ $2,906$ $71.4$ $(69.4-73.4)$ $1,500$ $31.8$ $(30.5-33.2)$ $243$ $20.7-28.3$ $193$ $2,906$ $71.4$ $(69.4-73.4)$ $1,555$ $35.3$ $(33.9-56.8)$ $538$ $64.7$ $(5.7,77)$ $243$ $20.7-28.3$ $193$ $2,905$ $75.7$ $(74.7-6)$ $83.3$ $83.3$ $79.3-86.6$ $53.8$ $552.92-97.5$ $2245$ $552.92-97.5$ $2245$ $552.92-97.5$ $2245$ $52.7/74.4-76.9$ $860$ <td< td=""><td>20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84</td><td>d income</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	20.2 (16.6–24.3) 123 39.9 (35.4–44.6) 267 21.7 (18.1–25.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84	d income								
1216 $300 (278-32.1)$ $1,216$ $276 (56.3-29.0)$ $399 (35.4-44.6)$ $267$ 398 $98 (8.5-11.2)$ $460$ $10.5 (9.6-11.4)$ $218$ $21.7 (18.1-25.8)$ $147$ $1,064$ $26.2 (24.2-28.2)$ $1,146$ $26.0 (24.8-27.4)$ $182$ $182 (14.7-22.3)$ $108$ $3332$ $82.0 (80.1-83.9)$ $3892$ $887 (87.7-89.6)$ $957$ $95.6 (92.9-97.3)$ $621$ $729$ $18.0 (16.1-19.9)$ $497$ $11.3 (10.4-12.3)$ $44$ $4.4 (2.6-7.1)$ $24$ $2,906$ $71.4 (69.4-73.4)$ $3,000$ $68.2 (66.8-69.5)$ $758$ $75.7 (71.7-79.3)$ $452$ $2,906$ $71.4 (69.4-73.4)$ $3,000$ $68.2 (66.8-69.5)$ $758$ $75.7 (71.7-79.3)$ $452$ $1,162$ $28.6 (26.6-30.6)$ $1,400$ $31.8 (30.5-33.2)$ $243 (20.7-283.3)$ $193$ $1,162$ $28.6 (26.6-30.6)$ $1,400$ $31.8 (30.5-33.2)$ $243 (20.7-283.3)$ $193$ $2,906$ $71.4 (69.4-73.4)$ $1,555$ $35.3 (33.9-36.8)$ $83.4$ $83.3 (79.3-86.6)$ $533$ $1,822$	39.9 (35.4-44.6) 267 21.7 (18.1-25.8) 147 18.2 (14.7-22.3) 108 95.6 (92.9-97.3) 621 4.4 (2.6-7.1) 24 75.7 (71.7-79.3) 452 24.3 (20.7-28.3) 193 83.3 (79.3-86.6) 538 16.7 (13.4-20.7) 107 85.9 (82.1-89.0) 561 14.1 (11.0-17.9) 84			4.2 (32.1–36.3)	1,578	35.9 (34.5–37.3)	202	20.2 (16.6–24.3)	123	19.1 (16.2–22.3
398         9.8 (8.5-11.2)         460         10.5 (9.6-11.4)         218         2.1.7 (18.1-25.8)         147           1,064         2.6.2 (2.4.2-28.2) $1,146$ $2.6.0$ ( $2.4.8-27.4$ ) $182$ $18.2$ ( $14.7-22.3$ ) $108$ 3,332         82.0 (80.1-83.9) $3,992$ $88.7$ ( $87.7-89.6$ ) $957$ $95.6$ ( $92.9-97.3$ ) $621$ $729$ $18.0$ ( $16.1-19.9$ ) $497$ $11.3$ ( $10.4-12.3$ ) $44$ $4.4$ ( $2.6-7.1$ ) $24$ $2,906$ $71.4$ ( $69.4-73.4$ ) $3,000$ $68.2$ ( $66.8-69.5$ ) $758$ $75.7$ ( $71.7-79.3$ ) $492$ $1,162$ $28.6$ ( $2630.6$ ) $1,400$ $31.8$ ( $30.5-33.2$ ) $243$ $20.7-28.3$ ) $193$ $1,162$ $28.6$ ( $2630.6$ ) $1,400$ $31.8$ ( $30.5-33.2$ ) $243$ $23.3$ ( $79.3-86.6$ ) $538$ $1,162$ $28.6$ ( $2630.6$ ) $1,400$ $31.8$ ( $30.5-33.2$ ) $243$ $20.7-28.3$ ) $193$ $2,245$ $55.2$ ( $52.9-57.5$ ) $2,845$ $64.7$ ( $63.2-66.1$ ) $16.7$ ( $13.4-20.7$ ) $107$ $2,932$ $72.1$ ( $69.9-74.1$ )<	21.7 (18.1–5.8) 147 18.2 (14.7–22.3) 108 95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84	50,000		0.0 (27.8–32.1)	1,216	27.6 (26.3–29.0)	399	39.9 (35.4–44.6)	267	41.4 (37.6–45.
1,064 $26.2$ ( $24.2-28.2$ )         1,146 $26.0$ ( $24.8-27.4$ )         182         182.( $14.7-22.3$ )         108           3,332         82.0 ( $80.1-83.9$ )         3,892         88.7 ( $87.7-89.6$ )         957         95.6 ( $92.9-97.3$ )         621           729         18.0 ( $16.1-19.9$ )         497         11.3 ( $10.4-12.3$ )         44         2.6-7.1)         24           2,906         71.4 ( $69.4-73.4$ )         3,000         68.2 ( $66.8-69.5$ )         758         75.7 ( $71.7-79.3$ )         452           2,906         71.4 ( $69.4-73.4$ )         3,000         68.2 ( $66.8-69.5$ )         758         75.7 ( $71.7-79.3$ )         452           1,162         28.6 ( $26.6-30.6$ )         1,400         31.8 ( $30.5-33.2$ )         243         20.7-28.3)         193           1,822         44.8 ( $42.5-47.1$ )         1,555         35.3 ( $9.3-9.66.1$ )         1,67         16.7 ( $13.4-20.7$ )         107           2,245         55.2 ( $52.9-57.5$ )         2,845 $64.7$ ( $63.2-66.1$ )         167         16.7 ( $13.4-20.7$ )         107           2,932         72.1 ( $69.9-74.1$ )         3,330         75.7 ( $74.4-76.9$ )         860         85.9 ( $82.1-89.0$ )         561           2,932         27.9 ( $25.9-30.1$ )         1,070         24.3 ( $2.3.1-25.6$ )<	18.2 (14.7-22.5)       108         95.6 (92.9-97.3)       621         4.4 (2.6-7.1)       24         75.7 (71.7-79.3)       452         24.3 (20.7-28.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       107         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84	0000	ć	9.8 (8.5–11.2)	460	10.5 (9.6–11.4)	218	21.7 (18.1–25.8)	147	22.8 (19.7–26.
3,332 $82.0$ $(80.1-83.9)$ $3,892$ $88.7$ $(87.7-89.6)$ $957$ $95.6$ $(92.9-97.3)$ $621$ $729$ $18.0$ $(16.1-19.9)$ $497$ $11.3$ $(10.4-12.3)$ $44$ $4.4$ $(2.6-7.1)$ $24$ $2,906$ $71.4$ $(69.4-73.4)$ $3,000$ $68.2$ $(66.8-69.5)$ $758$ $75.7$ $(71.7-79.3)$ $452$ $2,906$ $71.4$ $(69.4-73.4)$ $3,000$ $68.2$ $(66.8-69.5)$ $758$ $75.7$ $(71.7-79.3)$ $452$ $1,162$ $28.6$ $(26.6-30.6)$ $1,400$ $31.8$ $(30.5-33.2)$ $243$ $20.7-28.3$ $193$ $1,822$ $44.8$ $(42.5-47.1)$ $1,555$ $35.3$ $(33.9-36.8)$ $834$ $83.3$ $(79.3-86.6)$ $538$ $1,822$ $55.2$ $(52.9-57.5)$ $2,845$ $64.7$ $(63.2-66.1)$ $167$ $16.7$ $(13.4-20.7)$ $107$ $2,232$ $72.1$ $(69.9-74.1)$ $3,330$ $75.7$ $(74.4-76.9)$ $860$ $85.9$ $82.1-89.0)$ $561$ $1,136$ $27.9$ $(25.9-30.1)$ $1,070$ $24.3$ $(23.1-25.6)$ $141$ $14.1$ $(11.0-17.9)$ $84$	95.6 (92.9–97.3) 621 4.4 (2.6–7.1) 24 75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84		7	6.2 (24.2–28.2)	1,146	26.0 (24.8–27.4)	182	18.2 (14./-22.3)	108	16./ (14.1–19.
3,332 $82.0$ ( $60.1-85.9$ ) $3,892$ $88.7$ ( $87.7-89.6$ ) $957$ $95.6$ ( $92.9-97.3$ ) $0.21$ $729$ $18.0$ ( $16.1-19.9$ ) $497$ $11.3$ ( $10.4-12.3$ ) $44$ $4.4$ ( $2.6-7.1$ ) $24$ $2,906$ $71.4$ ( $69.4-73.4$ ) $3,000$ $68.2$ ( $66.8-69.5$ ) $758$ $75.7$ ( $71.7-79.3$ ) $452$ $2,906$ $71.4$ ( $69.4-73.4$ ) $3,000$ $68.2$ ( $66.8-69.5$ ) $758$ $75.7$ ( $71.7-79.3$ ) $452$ $1,162$ $28.6$ ( $26.6-30.6$ ) $1,400$ $31.8$ ( $30.5-33.2$ ) $243$ $20.7-28.3$ ) $193$ $1,162$ $28.6$ ( $26.6-30.6$ ) $1,400$ $31.8$ ( $30.5-33.2$ ) $243$ $20.7-28.3$ ) $193$ $1,222$ $44.8$ ( $42.5-47.1$ ) $1,555$ $35.3$ ( $33.9-36.8$ ) $834$ $833$ ( $79.3-86.6$ ) $538$ $2,245$ $55.2$ ( $52.9-57.5$ ) $2,845$ $64.7$ ( $63.2-66.1$ ) $16.7$ ( $13.4-20.7$ ) $107$ $2,932$ $72.7$ ( $74.4-76.9$ ) $860$ $85.9$ ( $82.1-89.0$ ) $561$ $1,1136$ $27.9$ ( $25.9-30.1$ ) $1,070$ $24.3$ ( $23.1-25.6$ ) $141$ $14.1$ ( $11.0-17.9$ ) $84$ <td>9.5. (9.2.9-9.7.3) 0.21 4.4 (2.6-7.1) 24 75.7 (71.7-79.3) 452 24.3 (20.7-28.3) 193 83.3 (79.3-86.6) 538 16.7 (13.4-20.7) 107 85.9 (82.1-89.0) 561 14.1 (11.0-17.9) 84</td> <td></td> <td>č</td> <td></td> <td></td> <td></td> <td>r L</td> <td></td> <td></td> <td></td>	9.5. (9.2.9-9.7.3) 0.21 4.4 (2.6-7.1) 24 75.7 (71.7-79.3) 452 24.3 (20.7-28.3) 193 83.3 (79.3-86.6) 538 16.7 (13.4-20.7) 107 85.9 (82.1-89.0) 561 14.1 (11.0-17.9) 84		č				r L			
7.29       10.00 (10.1-17.57)       470       11.5 (10.4-12.50)       444       4.4 (2.0-7.1)       24         2,906       71.4 (69.4-73.4)       3,000       68.2 (66.8-69.5)       758       75.7 (71.7-79.3)       452         1,162       28.6 (26.6-30.6)       1,400       31.8 (30.5-33.2)       243       20.7-28.3)       193         1,822       44.8 (42.5-47.1)       1,555       35.3 (33.9-36.8)       834       833.3 (79.3-86.6)       538         2,245       55.2 (52.9-57.5)       2,845       64.7 (63.2-66.1)       167       16.7 (13.4-20.7)       107         2,932       72.1 (69.9-74.1)       3,330       75.7 (74.4-76.9)       860       85.9 (82.1-89.0)       561         1,136       27.9 (25.9-30.1)       1,070       24.3 (23.1-25.6)       141       14.1 (11.0-17.9)       84	4.4 (2.0-7.1)       24         75.7 (71.7-79.3)       452         24.3 (20.7-28.3)       193         83.3 (79.3-86.6)       538         16.7 (13.4-20.7)       107         85.9 (82.1-89.0)       561         14.1 (11.0-17.9)       84		x -	52.0 (80.1–83.9) 80 (16 1 100)	3,892	(0.64.7.78) /.88 (0.01.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7	166	95.0 (92.9-97.3) 11 5 5 7 1 1	179	96.3 (94.5–97.
2,906         71.4 (69.4-73.4)         3,000         68.2 (66.8-69.5)         758         75.7 (71.7-79.3)         452           1,162         28.6 (26.6-30.6)         1,400         31.8 (30.5-33.2)         243         20.7-28.3)         193           1,822         44.8 (42.5-47.1)         1,555         35.3 (33.9-36.8)         834         83.3 (79.3-86.6)         538           2,245         55.2 (52.9-57.5)         2,845         64.7 (63.2-66.1)         167         16.7 (13.4-20.7)         107           2,932         72.1 (69.9-74.1)         3,330         75.7 (74.4-76.9)         860         85.9 (82.1-89.0)         561           1,136         27.9 (25.9-30.1)         1,070         24.3 (23.1-25.6)         141         14.1 (11.0-17.9)         84	75.7 (71.7–79.3) 452 24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84		-	0.0 (10.1-12.2)	49/	(6.21-4.01) 6.11	++	4.4 (2.0-7.1)	24	(6.6-6.2) /.6
Country Total field conditions* $1,162$ 28.6 (26.6–30.6) $1,400$ 31.8 (30.5–33.2) 243 24.3 (20.7–28.3) 193 onic medical conditions* $1,822$ 44.8 (42.5–47.1) $1,555$ 35.3 (33.9–36.8) 834 83.3 (79.3–86.6) 538 onic medical conditions* $2,245$ 55.2 (52.9–57.5) 2,845 64.7 (63.2–66.1) 167 16.7 (13.4–20.7) 107 ntal health problem* $2,932$ 72.1 (69.9–74.1) 3,330 75.7 (74.4–76.9) 860 85.9 (82.1–89.0) 561 1,136 27.9 (25.9–30.1) 1,070 24.3 (23.1–25.6) 141 14.1 (11.0–17.9) 84	24.3 (20.7–28.3) 193 83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			1.4 (69.4–73.4)	3.000	68.2 (66.8–69.5)	758	75.7 (71.7–79.3)	452	70.1 (66.4–73.
onic medical conditions* 1,822 44.8 (42.5-47.1) 1,555 35.3 (33.9-36.8) 834 83.3 (79.3-86.6) 538 2,245 55.2 (52.9-57.5) 2,845 64.7 (63.2-66.1) 167 167 16.7 (13.4-20.7) 107 ntal health problem* 2,932 72.1 (69.9-74.1) 3,330 75.7 (74.4-76.9) 860 85.9 (82.1-89.0) 561 1,136 27.9 (25.9-30.1) 1,070 24.3 (23.1-25.6) 141 14.1 (11.0-17.9) 84	83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			8.6 (26.6–30.6)	1,400	31.8 (30.5–33.2)	243	24.3 (20.7–28.3)	193	29.9 (26.5–33.6)
1,822       44.8 (42.5-47.1)       1,555       35.3 (33.9-36.8)       834       83.3 (79.3-86.6)       538         2,245       55.2 (52.9-57.5)       2,845       64.7 (63.2-66.1)       167       16.7 (13.4-20.7)       107         antal health problem <sup>*</sup> 2,932       72.1 (69.9-74.1)       3,330       75.7 (74.4-76.9)       860       85.9 (82.1-89.0)       561         1,136       27.9 (25.9-30.1)       1,070       24.3 (23.1-25.6)       141       14.1 (11.0-17.9)       84	83.3 (79.3–86.6) 538 16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84									
2,245 55.2 (52.9–57.5) 2,845 64.7 (63.2–66.1) 167 16.7 (13.4–20.7) 107 ntal health problem <sup>#</sup> 2,932 72.1 (69.9–74.1) 3,330 75.7 (74.4–76.9) 860 85.9 (82.1–89.0) 561 1,136 27.9 (25.9–30.1) 1,070 24.3 (23.1–25.6) 141 14.1 (11.0–17.9) 84	16.7 (13.4–20.7) 107 85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84			!4.8 (42.5–47.1)	1,555	35.3 (33.9–36.8)	834	83.3 (79.3–86.6)	538	83.4 (80.3–86.1)
na nearu proven 2,932 72.1 (69.9–74.1) 3,330 75.7 (74.4–76.9) 860 85.9 (82.1–89.0) 561 1,136 27.9 (25.9–30.1) 1,070 24.3 (23.1–25.6) 141 14.1 (11.0–17.9) 84	85.9 (82.1–89.0) 561 14.1 (11.0–17.9) 84	*		(5.2 (52.9–57.5)	2,845	64.7 (63.2–66.1)	167	16.7 (13.4–20.7)	107	16.6 (13.9–19.6
1,136 27.9 (25.9-30.1) 1,070 24.3 (23.1-25.6) 141 14.1 (11.0-17.9) 84	100 (0.20-1-20) (2.20 14.1 (11.0-17.9) 84			1112 009/10		757 (77 4 75 0)	090	85 0 (87 1 80 0)	561	07 0 /07 1 00
				7.9 (25.9–30.1)	0cc,c 1.070	74.3 (73.1–75.6)	600 141	(0.60-1.20) (0.00) 14.1 (11.0-17.9)	10C	0/.0 (04.1-09.4) 13.0 (10.6-15.9)
weichting of the data can result in rounding discremencies or totals not adding. (Fontidence Interval Mission data were evoluted from descriptive analyses	arguing of the address for a comparison of zerial and second second second second second and accordence and second se	veichting of the data can result in rounding discremancies or tota	tals not add	ling (1. Confidence In:	terval Missing	data were excluded from de	scrintive analyse			

Table 1. Weighted and unweighted socio-demographic characteristics of ALL respondents (excluding the respondents who answered "I have already been vaccinated").

e2079345-4 😸 B. WANG ET AL.




Figure 1. Weighted likelihood rates of accepting COVID-19 vaccination by survey week and key events reported and announcements made during the survey period.

#### **Reasons for not considering COVID-19 vaccination**

Among respondents aged  $\geq 16$  years (weighted n = 1,622) who were not "very likely" to be vaccinated, vaccine safety concerns (Tables S5 and S6), perceived low risk of infection (Tables S7 and S8), and perceived lack of information about COVID-19 vaccines (Tables S9 and S10) were the top three barriers to COVID-19 vaccination (Figure 2 and Figure S1). Only a small proportion of respondents indicated that they were antivaccination (2.5%) (Table S11) or believed a COVID-19 vaccine would not be effective for this virus (5.2%) (Tables S12 and S13).

In the weighted logistic regression analysis, predictors identified for lower risk perception about COVID-19 (Table S8) and perceived inadequate information about the vaccine (Table S10) were similar to those for vaccine willingness and vaccine safety confidence (age, gender, Aboriginal people, socioeconomic status, education attainment, employment). However, the COVID-19 vaccine rollout had a significant impact on vaccine safety concerns (Table S6) as the percentage of respondents who had vaccine safety concerns reduced from 35.7% to 30.7% (aOR: 0.80 [95% CI, 0.65–0.98]). In addition, respondents who were not married or did not have a chronic medical illness were more likely to have lower COVID-19 risk perception.

# Discussion

Using a large representative sample, we showed that those who were hesitant to receive the vaccine reported concerns with vaccine safety, considering the risk from COVID-19 was low or felt they did not know enough about the vaccine. The study also presented data from the perspective of parents having their child immunized and found a smaller proportion were very likely to consent to their child being vaccinated compared with the adult population.

Although the willingness to vaccinate has been investigated in Australia and other countries,<sup>24-27</sup> the questions, responses, and methods varied between studies and results may not be comparable. However, what is common is the trend of willingness to vaccinate against COVID-19 fluctuating over time.14-17,28-30 This study also showed fluctuating support over the 4-month data collection period. This is mirrored by findings in a longitudinal survey reporting 55% of Australians indicated that they would definitely get vaccinated in April 2021 with a lower rate reported in January 2021 and a higher rate reported in August 2020.<sup>16</sup> Previous research showed vaccine willingness decreased except for those living in metropolitan Victoria during the period of the Victorian second lockdown, which may imply that vaccine willingness was associated with environmental factors and the degree of threat experienced during the pandemic.<sup>14,31</sup> Vaccine attitudes were also compared prior to and after the COVID-19 vaccine rollout. Although vaccine confidence, perceived disease risk, perceived inadequate information and vaccine effectiveness concerns remained unchanged, vaccine willingness increased, and vaccine safety concerns decreased significantly after the rollout. This may be due to people who were hesitant previously becoming more willing to receive the COVID-19 vaccine with less safety concerns, after an increasing number of their family members and friends had received the COVID-19 vaccine without any major side effects. Safety of COVID-19 vaccines and social norms (e.g. more people getting vaccinated) most likely influence individuals' intentions to receive a COVID-19 vaccine. Similar to survey findings reported in Australia and other developed countries,<sup>16</sup> it appears vaccination has been increasingly accepted as a path out of restriction and confinement with interest in being vaccinated varying alongside key pandemic or vaccine-related events.

Social, attitudinal, political, health, and demographic factors associated with willingness to vaccinate with COVID-19 vaccine have been inconsistently reported and Table 2. Weighted and adjusted odds ratios of likelihood (very likely) of getting COVID-19 vaccination in the subsample of respondents aged 16+ (comparing "very likely" with "somewhat/not very/not at all likely/don't know").

	Respondents who were very likely to get vaccinated		Multivariate logistic regression	
	n/N (Weighted)	% (95% Cl) (Weighted)	Adjusted Odds Ratio	95% CI
Age				
16-29 yrs	356/705	50.5 (43.2–57.8)	Reference	
30-49 yrs	600/1,200	50.0 (45.2–54.8)	0.93	0.64–1.34
50-69 yrs	910/1,397	65.2 (62.2–68.0)	1.82	1.28–2.59
≥70 yrs	580/753	77.0 (73.7–80.0)	3.01	2.02-4.62
Gender				
Male	1,190/1,897	62.7 (59.1–66.2)	Reference	
Female	1,255/2,155	58.2 (55.3–61.1)	0.70	0.57-0.86
Aboriginal and/or Torres Strait Islander Status				
No	2,403/3,957	60.7 (58.4–63.0)	Reference	
Yes	35/80	42.4 (25.2–61.7)	0.76	0.30-1.92
SEIFA				
lowest quintile	396/772	51.3 (45.9–56.7)	Reference	
low quintile	513/873	58.8 (54.0-63.4)	1.17	0.87–1.59
middle quintile	547/914	59.9 (55.1–64.5)	1.32	0.98-1.80
high quintile	445/720	61.8 (56.0–67.3)	1.34	0.95–1.88
highest quintile	543/775	70.1 (65.1–74.7)	1.76	1.26-2.48
Marital status				
Single	1,056/1,844	57.3 (53.6–60.8)	Reference	
Married/de facto	1,375/2,179	63.1 (60.1–66.0)	1.13	0.91-1.39
Education level	.,,			
Lower than Year 12 education	484/852	56.8 (51.9–61.5)	Reference	
≥ Year 12/TAFE/certificate/diploma	1,478/2,490	59.4 (56.2–62.4)	1.46	1.14–1.87
Degree or higher	473/690	68.6 (64.5–72.5)	2.54	1.85-3.49
Employment			2101	1100 0117
Unemployed	79/181	43.9 (33.6–54.9)	Reference	
Employed^	1,253/2,221	56.4 (53.1–59.7)	1.48	0.91–2.41
Other^^	1,113/1,653	67.3 (64.2–70.3)	1.75	1.06-2.90
СОВ	1,113,1,035	07.5 (04.2 70.5)	1.75	1.00 2.90
English main language	2,036/3,321	61.3 (58.8–63.7)	Reference	
Non English speaking	405/728	55.7 (49.6–61.6)	0.81	0.60-1.10
Area of residence	-103/720	55.7 (49.0-01.0)	0.01	0.00-1.10
Metro. Adelaide	1,764/2,899	60.9 (58.1–63.6)		
SA Country	682/1,156	59.0 (54.9–63.0)		
Chronic medical conditions*	002/1,150	59.0 (54.9-05.0)		
No	1,003/1,817	55.2 (51.4–58.9)	Reference	
Yes			1.18	0.94–1.48
Mental health problem#	1,442/2,237	64.5 (61.7–67.2)	1.10	0.94-1.40
-	1 021/2 024	62.6 (50.0, 65.2)	Poforonco	
No Yes	1,831/2,924	62.6 (59.9–65.2) 54.4 (49.9–58.9)	Reference 0.88	0.70-1.10
	615/1,130	54.4 (49.9–58.9)	0.00	0.70-1.10
Survey date	047/1 600		Deferrer	
Prior to the COVID-19 vaccination roll out	947/1,689	56.1 (52.4–59.6)	Reference	114 170
During the COVID-19 vaccination roll out	1,498/2,365	63.4 (60.4–66.2)	1.39	1.14–1.70


^ Employed included full-time employed, part-time employed, and casual employment.

^^ Other category includes respondents engaged in home duties, unable to work, carers, volunteers, students, retired, and any other response.

\* If participants responded "Yes" to any of these medical conditions: diabetes, asthma, chronic bronchitis/emphysema, Image result for cardiovascular disease, arthritis, or cancer, they were classified as having a chronic disease.

# If participants responded "Yes" to any of these mental health conditions: anxiety, depression, stress, or others, they were classified as having a mental health problem.

varied between studies. Age, gender, a range of socioeconomic factors, identifying as Aboriginal, health literacy, political affiliations, use of traditional media, chronic illness, levels of religiosity, confidence in government or hospitals, supportive attitudes toward migration, perceived disease severity, trust in science, willingness to vaccinate for influenza, experiences of discrimination and remoteness of residence have been reported to be relevant to COVID-19 vaccine willingness.<sup>12,13,15,16,24–30,32–36</sup> This study found that females, unemployed people, low educational attainment, people living in lower socioeconomic areas, and younger people were less willing to be vaccinated. There was also a lower proportion of Aboriginal people who were very likely to be vaccinated, but this did not reach traditional



# The question regarding reasons why they were not very likely to receive the COVID-19 vaccine were grouped by themes. See Supplementary Figure 1 in detail.

Figure 2. Reasons for not considering COVID-19 vaccination, by subgroup themes# (multiple responses allowed). # The question regarding reasons why they were not very likely to receive the COVID-19 vaccine were grouped by themes. See Figure S1 in detail.

levels of significance, likely due to a small sample size. Further, Aboriginal people were less likely to be very confident about vaccine safety and more likely to have perceived insufficient information about the vaccine. Similar to our study, young age has also been reported to be a significant factor related to low vaccine acceptance in other surveys.<sup>28,33</sup> In line with the Australian survey conducted in April and August 2020,<sup>29</sup> we did not find an association between chronic disease and the willingness to vaccinate. Interestingly, respondents who were married, had chronic illness, and were employed/retired/students/worked without pay were less likely to perceive low risk of disease, which has not been investigated in previous surveys.

In all, 11% of respondents were not at all confident about vaccine safety and 46% were somewhat confident with only one third being very confident. Vaccine safety concerns were also the top reason why respondents did not choose "very likely" to get vaccinated. Other studies have also shown that vaccine safety may be the most important concern respondents had about COVID-19 vaccine and one of the main reasons for hesitancy of the vaccine.<sup>28,33</sup>

Around 48% of parents or caregivers indicated that they were very likely to get their children vaccinated in this study. Similar results were reported in Japan and the UK with a higher percentage of respondent's willingness to get COVID-19 vaccination for themselves than for their children.<sup>19,20</sup> One of the main concerns for parents has been the potential side effects of the COVID-19 vaccine.<sup>19,20</sup> Previous research has found vaccine acceptance is influenced by vaccine efficacy and perceptions of disease risk. Prior to the Delta and Omicron strain outbreaks, children were reported to have a lower susceptibility to COVID-19. Parents might more often balance the risks and benefits to their child when making a vaccination decision, rather than considering the benefits to communities and society.<sup>37</sup> The COVID-19 vaccination program has been extended to all children aged five and over. Monitoring parental willingness would be warranted to modify current vaccination strategies to improve the vaccine coverage rates in children.

This study found little evidence of an increase in any generalized aversion to vaccines,<sup>28</sup> with very few vaccine hesitant respondents indicating that they did not believe in vaccinations.

This study has some strengths and limitations. The survey was administered in a representative sample with a large sample size, although it was undertaken in a state with low level of COVID-19 disease. Weighting was applied to the analyses to compensate for the selection of specific observations with oversampling, non-responses, and other types of bias. This is a cross-sectional, and not a longitudinal or repeated survey study. Comparisons between different respondents over time should be interpreted with caution.

The overall effectiveness of the vaccine rollout will depend on the widespread community trust of COVID-19 vaccines. Despite enormous efforts to deliver the COVID-19 vaccine rollout, governments, health professionals, and COVID-19 vaccination providers may need to address vaccine safety concerns by providing evidence-based information, and enhancing vaccine safety messaging in Indigenous languages and languages other than English for migrants, refugees, and other limited-English-proficient populations. Our study also highlights the need for vaccination campaigns targeting healthy populations with young age, female gender, unemployment, and low education and/or socioeconomic level, as well as culturally appropriate information for Aboriginal and Torres Strait Islander people. Future research on a large longitudinal or repeated survey sample is paramount to monitor vaccine willingness, and adjust communication strategies developed for immunization providers and health professionals.

# Abbreviations

ABS	Australian Bureau of Statistics
COB	Country of Birth
SAPHS	South Australian Population Health Survey
SEIFA	Socio-Economic Index For Areas

#### **Author's contribution**

Conceptualization: H. M., B. W., R. N., K. D, and B. K.; methodology: H. M., B. W., R. N., K. D, and B. K.; formal analysis, B. W. and B. K.; data curation: R. N., K. D, and B. K.; writing-original draft preparation: B. W.; writing-review and editing: H. M., B. W., R. N., K. D, and B. K.

# **Disclosure statement**

H. M. is an investigator on vaccine trials sponsored by the GSK group of companies, Pfizer, Sanofi, and Merck. H. M.'s and B. W.'s institution receives funding for investigator-led studies from industry, including Pfizer and Sanofi Pasteur; H. M. and B. W. receive no personal payments from the industry. All other authors report no potential conflicts of interest.

# **Ethical approval statement**

This survey was approved by the Department for Health and Wellbeing Human Research Ethics Committee (HREC/18/SAH/11/AM04).

# Funding

H.M. is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship [APP1155066].

# ORCID

Helen Marshall (D) http://orcid.org/0000-0003-2521-5166

# References

- McIntosh K, Hirsch MS, Bloom A COVID-19: epidemiology, virology, and prevention. Wolters Kluwer, UpToDate; 2022 Mar 1 [accessed 2022 Apr 19]. https://www.uptodate.com/contents/ covid-19-epidemiology-virology-and-prevention
- 2. AIHW. 2021. The first year of COVID-19 in Australia: direct and indirect health effects. Cat. no. PHE 287. Canberra:AIHW.
- Chriscaden K Impact of COVID-19 on people's livelihoods, their health and our food systems. Joint statement by ILO, FAO, IFAD and WHO. WHO; 2020 Oct 13 [accessed 2022 Apr 19]. https:// www.who.int/news/item/13-10-2020-impact-of-covid-19-onpeople%27s-livelihoods-their-health-and-our-food-systems
- Viana J, van Dorp CH, Nunes A, Gomes MC, van Boven M, Kretzschmar ME, Veldhoen M, Rozhnova G. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun. 2021 Jun 16;12(1):3674. doi:10.1038/s41467-021-23938-8.
- Yamey G, Schaferhoff M, Hatchett R, Pate M, Zhao F, McDade KK. Ensuring global access to COVID-19 vaccines. Lancet. 2020 May 2;395(10234):1405–06. doi:10.1016/S0140-6736(20)30763-7.
- 6. WHO. Weekly epidemiological update on COVID-19 27 April 2022. Emergency Situational Updates (Edition 89). WHO; 2022 April 27 [accessed 2022 April 28]. https://www.who. int/publications/m/item/weekly-epidemiological-update-on-covid -19-27-april-2022
- 7. WHO. The Omicron variant: sorting fact from myth. WHO; 2022 Jan 19 [acessed 2022 Apr 19]. https://www.euro.who.int/en/healthtopics/health-emergencies/pages/news/news/2022/01/the-omicron -variant-sorting-fact-from-myth
- COVID Live. South Australia daily confirmed cases: COVID LIVE. 2022 April 19 [accessed 2022 April 19]. https://covidlive.com.au/sa
- McBryde ES, Meehan MT, Sziklay J, et al. Vaccination is Australia's most important COVID-19 public health action, even though herd immunity is unlikely. medRxiv; 2021 [accessed 2022 April 19]. doi:10.1101/2021.07.16.21260642.

- Australian Government Department of Health. COVID-19 vaccine rollout update – 18 April 2022. Commonwealth of Australia, Department of Health; 2022 Apr 18 [accessed 2022 Apr 19]. https://www.health.gov.au/resources/publications/covid-19vaccine-rollout-update-18-april-2022
- Australian Government Department of Health. ATAGI statement on the Omicron variant and timing of COVID-19 booster vaccination. Commonwealth of Australia, Department of Health; 2021 Dec 24 [accessed 2021 Dec 29]. https://www.health.gov.au/ news/atagi-statement-on-the-omicron-variant-and-the-timing-ofcovid-19-booster-vaccination
- Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ, Ayre J, Batcup C, Copp T, Cornell S, Dakin T. Sydney Health Literacy Lab-COVID-group. Willingness to vaccinate against COVID-19 in Australia. Lancet Infect Dis. 2021;21(3):318–19. doi:10.1016/ S1473-3099(20)30559-4.
- Seale H, Heywood AE, Leask J, Sheel M, Durrheim DN, Bolsewicz K, Kaur R. Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine. BMC Infect Dis. 2021 Jan 28;21(1):120. doi:10.1186/s12879-021-05833-1.
- To QG, Stanton R, Khalesi S, Williams SL, Alley SJ, Thwaite TL, Fenning AS, Vandelanotte C. Willingness to vaccinate against COVID-19 declines in Australia, except in lockdown areas. Vaccines (Basel). 2021 May 10;9(5):479. doi:10.3390/ vaccines9050479.
- Biddle N, Edwards B, Gray M, Sollis K. Change in vaccine willingness in Australia: August 2020 to January 2021. *medRxiv*; 2021 [accessed 2022 Apr 19]. doi:10.1101/ 2021.02.17.21251957.
- Biddle N, Edwards B, Gray M, Sollis K. Vaccine willingness and concerns in Australia: August 2020 to April 2021. ANU Centre for Social Research and Methods; 2021 [accessed 2022 Apr 19]. https://csrm.cass.anu.edu.au/research/publications/vac cine-willingness-and-concerns-australia-august-2020-april -2021-1
- Biddle N, Edwards B, Gray M, Sollis K Determinants of COVID-19 vaccination and views of parents about vaccination of children in Australia: August 2021. ANU Centre for Social Research and Methods. 2021 [accessed 2022 Apr 19]. https://csrm.cass.anu.edu. au/research/publications/determinants-covid-19-vaccination-andviews-parents-about-vaccination-children
- Rhodes A, Hoq M, Measey MA, Danchin M. Intention to vaccinate against COVID-19 in Australia. Lancet Infect Dis. 2021;21(5):e110. doi:10.1016/S1473-3099(20)30724-6.
- Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. 2020 Nov 17;38(49):7789–98. doi:10.1016/j.vaccine.2020.10.027.
- Yoda T, Katsuyama H. Parents' hesitation about getting their children vaccinated against COVID-19 in Japan. Hum Vaccin Immunother. 2021 Dec 2;17(12):4993–98. doi:10.1080/ 21645515.2021.1981087.
- The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. 9th ed. AAPOR; 2016.
- 22. Australian Bureau of Statistics. 2033.0.55.001- Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016. Australian Bureau of Statistics; 2018 Mar 27 [accessed 2021 Aug 3]. https://www.abs.gov.au/ausstats/ abs@.nsf/Lookup/by%20Subject/2033.0.55.001 2016 Main% 20Features FAQs%20-%20SEIFA%202016 4
- Australian Bureau of Statistics. 1200.0.55.004- Country of Birth Standard, 2012, Version 1.0. Australian Bureau of Statistics; 2012 Sep 26 [accessed 2021 August 3]. https://www.abs.gov.au/ausstats/ abs@.nsf/Lookup/1200.0.55.004main+features42012,%20Version %201.0
- Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: a rapid systematic review. Vaccines (Basel). 2020 Dec 30;9(1):16. doi:10.3390/vaccines9010016.

- Nehal KR, Steendam LM, Campos Ponce M, van der Hoeven M, Smit GSA. Worldwide vaccination willingness for COVID-19: a systematic review and meta-analysis. Vaccines (Basel). 2021 Sep 24;9(10):1071. doi:10.3390/vaccines9101071.
- Robinson E, Jones A, Lesser I, Daly M. International estimates of intended uptake and refusal of COVID-19 vaccines: a rapid systematic review and meta-analysis of large nationally representative samples. Vaccine. 2021 Apr 8;39(15):2024–34. doi:10.1016/j. vaccine.2021.02.005.
- Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021 Feb 16;9(2):160. doi:10.3390/vaccines9020160.
- Smith DT, Attwell K, Evers U. Support for a COVID-19 vaccine mandate in the face of safety concerns and political affiliations: an Australian study. Politics. 2021:026339572110090. doi:10.1177/ 02633957211009066.
- 29. Alley SJ, Stanton R, Browne M, To QG, Khalesi S, Williams SL, Thwaite TL, Fenning AS, Vandelanotte C. As the pandemic progresses, how does willingness to vaccinate against COVID-19 evolve? Int J Environ Res Public Health. 2021 Jan 19;18(2):797. doi:10.3390/ijerph18020797.
- Attwell K, Lake J, Sneddon J, Gerrans P, Blyth C, Lee J, Samy AM. Converting the maybes: crucial for a successful COVID-19 vaccination strategy. PLoS One. 2021 Jan 20;16(1):e0245907. doi:10.1371/journal.pone.0245907.
- Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine. 2011 Sep 2;29(38):6472-84. doi:10.1016/j. vaccine.2011.06.107.

- 32. Davis SR, Ampon RD, Poulos LM, Marks GB, Toelle BG, Reddel HK. Willingness to receive vaccination against COVID-19: results from a large nationally representative Australian population survey. *medRxiv*; 2021 [accessed 2022 Apr 19]. doi:10.1101/2021.07.22.21260551.
- 33. Dodd RH, Pickles K, Cvejic E, Cornell S, Isautier JMJ, Copp T, Nickel B, Bonner C, Batcup C, Muscat DM, et al. Perceived public health threat a key factor for willingness to get the COVID-19 vaccine in Australia. Vaccine. 2022 Apr 14;40(17):2484–90. doi:10.1016/j.vaccine.2021.08.007.
- Edwards B, Biddle N, Gray M, Sollis K, Di Gennaro F. COVID-19 vaccine hesitancy and resistance: correlates in a nationally representative longitudinal survey of the Australian population. PLoS One. 2021 Mar 24;16(3):e0248892. doi:10.1371/journal. pone.0248892.
- Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021 ;27(2):225–28. doi:10.1038/ s41591-020-1124-9.
- 36. Trent M, Seale H, Chughtai AA, Salmon D, MacIntyre CR. Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: a comparative survey of five large cities in the United States, United Kingdom, and Australia. Vaccine. 2022 Apr 14;40 (17):2498–505. doi:10.1016/j.vaccine.2021.06.048.
- 37. Paterson P, Chantler T, Larson HJ. Reasons for non-vaccination: parental vaccine hesitancy and the childhood influenza vaccination school pilot programme in England. Vaccine. 2018 Aug 28;36(36):5397-401. doi:10.1016/j. vaccine.2017.08.016.